NAHDI MEDICAL COMPANY |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 136 SAR | +0.44% |
|
-4.09% | -0.73% |
| Mar. 18 | Nahdi Medical Company Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 18 | Nahdi Medical Posts Higher FY23 Net Profit, Revenue | MT |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 21,736 | 17,810 | 17,654 | - | - |
| Enterprise Value (EV) 1 | 21,828 | 18,075 | 17,923 | 17,796 | 17,640 |
| P/E ratio | 24.5 x | 19.9 x | 19.8 x | 18.4 x | 17.1 x |
| Yield | - | 4.01% | 3.97% | 4.35% | 4.92% |
| Capitalization / Revenue | 2.52 x | 2.04 x | 1.94 x | 1.84 x | 1.74 x |
| EV / Revenue | 2.53 x | 2.07 x | 1.97 x | 1.86 x | 1.73 x |
| EV / EBITDA | 13.6 x | 11.5 x | 11.1 x | 10.4 x | 9.68 x |
| EV / FCF | - | 18.4 x | 19.9 x | 19.5 x | 16.8 x |
| FCF Yield | - | 5.45% | 5.02% | 5.12% | 5.96% |
| Price to Book | 9.69 x | 7.92 x | 7.01 x | 6.38 x | 6.04 x |
| Nbr of stocks (in thousands) | 130,000 | 130,000 | 130,000 | - | - |
| Reference price 2 | 167.2 | 137.0 | 136.0 | 136.0 | 136.0 |
| Announcement Date | 3/20/23 | 3/17/24 | - | - | - |
1SAR in Million2SAR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 8,616 | 8,714 | 9,109 | 9,574 | 10,168 |
| EBITDA 1 | - | 1,599 | 1,578 | 1,615 | 1,716 | 1,822 |
| EBIT 1 | - | 1,003 | 961 | 953.5 | 1,024 | 1,106 |
| Operating Margin | - | 11.64% | 11.03% | 10.47% | 10.7% | 10.87% |
| Earnings before Tax (EBT) 1 | - | - | 944.2 | 993.2 | 1,086 | 1,182 |
| Net income 1 | 812.5 | 887.8 | 892.6 | 893.1 | 960.5 | 1,036 |
| Net margin | - | 10.3% | 10.24% | 9.8% | 10.03% | 10.19% |
| EPS 2 | 6.250 | 6.830 | 6.870 | 6.870 | 7.388 | 7.967 |
| Free Cash Flow 1 | - | - | 984.2 | 899 | 910.7 | 1,052 |
| FCF margin | - | - | 11.3% | 9.87% | 9.51% | 10.35% |
| FCF Conversion (EBITDA) | - | - | 62.37% | 55.67% | 53.06% | 57.73% |
| FCF Conversion (Net income) | - | - | 110.26% | 100.67% | 94.81% | 101.57% |
| Dividend per Share 2 | - | - | 5.500 | 5.400 | 5.918 | 6.685 |
| Announcement Date | 4/3/22 | 3/20/23 | 3/17/24 | - | - | - |
1SAR in Million2SAR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 2,239 | 2,159 | 2,138 | 2,105 | - | 2,163 | 2,214 | 2,224 |
| EBITDA | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | 305.8 | 278.5 | 153.9 | 263.2 | - | 229.8 | 215.1 | 256 |
| Operating Margin | - | 13.66% | 12.9% | 7.2% | 12.51% | - | 10.62% | 9.71% | 11.51% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - |
| Net income 1 | 237.5 | 268.5 | 253.8 | 128 | - | 265 | - | - | 177.5 |
| Net margin | - | 11.99% | 11.76% | 5.99% | - | - | - | - | 7.98% |
| EPS | 1.830 | 2.070 | - | 0.9900 | - | 2.040 | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 5/23/22 | 8/11/22 | 11/3/22 | 3/20/23 | 5/11/23 | 8/3/23 | 11/5/23 | 3/17/24 | - |
1SAR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 91.8 | 265 | 269 | 142 | - |
| Net Cash position 1 | - | - | - | - | - | 14.1 |
| Leverage (Debt/EBITDA) | - | 0.0574 x | 0.168 x | 0.1668 x | 0.0827 x | - |
| Free Cash Flow 1 | - | - | 984 | 899 | 911 | 1,052 |
| ROE (net income / shareholders' equity) | - | 46.2% | 37.9% | 35.9% | 36.4% | 36.4% |
| ROA (Net income/ Total Assets) | - | 19.2% | 17.3% | 16.7% | 17.2% | 17.9% |
| Assets 1 | - | 4,616 | 5,158 | 5,349 | 5,575 | 5,795 |
| Book Value Per Share 2 | - | 17.30 | 17.30 | 19.40 | 21.30 | 22.50 |
| Cash Flow per Share 2 | - | 12.80 | 10.50 | 10.10 | 10.40 | 9.070 |
| Capex 1 | - | 275 | 385 | 404 | 365 | 373 |
| Capex / Sales | - | 3.19% | 4.41% | 4.43% | 3.81% | 3.66% |
| Announcement Date | 4/3/22 | 3/20/23 | 3/17/24 | - | - | - |
1SAR in Million2SAR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
136
SAR
Average target price
155.4
SAR
Spread / Average Target
+14.29%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -0.73% | 4.69B | |
| -29.67% | 10.84B | |
| -28.54% | 6.06B | |
| +7.42% | 6.04B | |
| -11.41% | 5.86B | |
| +52.19% | 4.29B | |
| -12.31% | 3.61B | |
| -13.25% | 3.33B | |
| -6.93% | 3.01B | |
| -2.36% | 2.8B |
- Stock Market
- Equities
- 4164 Stock
- Financials Nahdi Medical Company
